-
Mashup Score: 0Ripretinib Shows Better Efficacy Than Sunitinib in Imatinib-Pretreated Patients With KIT-Mutated GIST - 11 month(s) ago
INTRIGUE study results show that patients with gastrointestinal stromal tumor who harbor certain KIT mutations have significantly improved responses and survival with ripretinib treatment.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Phase 3 Study Evaluates Ripretinib for KIT Exon 11-Mutated GIST - 1 year(s) ago
Ripretinib will be evaluated in a phase 3 trial for patients with gastrointestinal stromal tumor after being added to the NCCN guidelines and receiving 2 breakthrough therapy designations from the FDA.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Ripretinib now has 2 breakthrough therapy designations from the FDA and has been added to the NCCN guidelines for gastrointestinal stromal tumor.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Ripretinib Shows Better Efficacy Than Sunitinib in Imatinib-Pretreated Patients With KIT-Mutated GIST - 1 year(s) ago
INTRIGUE study results show that patients with gastrointestinal stromal tumor who harbor certain KIT mutations have significantly improved responses and survival with ripretinib treatment.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Ripretinib Yields Clinically Meaningful Benefit in Advanced GIST - 4 year(s) ago
Patients given ripretinib for advanced GIST in the INVICTUS trial had improved PFS and OS, according to data presented at the virtual 2020 ESMO World Congress on GI Cancer.
Source: Oncology Leanring NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial - 4 year(s) ago
Ripretinib significantly improved median progression-free survival compared with placebo and had an acceptable safety profile in patients with advanced gastrointestinal stromal tumours who were resistant to approved treatments.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial - 4 year(s) ago
Ripretinib significantly improved median progression-free survival compared with placebo and had an acceptable safety profile in patients with advanced gastrointestinal stromal tumours who were resistant to approved treatments.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Findings from the INTRIGUE study show that patients with #GIST who harbor certain KIT mutations have significantly improved responses and survival with #ripretinib treatment. @DanaFarber https://t.co/GAHX0qAAED